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Abstract
Metastatic breast cancer is the leading cause of cancer-related deaths among women
worldwide. Triple-negative breast cancer (TNBC) is the most aggressive, accounting
for 15-20% of all breast cancer cases. As TNBC cells lack the expression of hormone
receptors estrogen receptors (ER) and progesterone receptors (PR) and human
epidermal growth factor receptor 2 (HER2), TNBCs are unresponsive to hormonal
therapy and often become highly resistant when exposed to standard chemotherapy,
which has been identifies as a major obstacle in TNBC treatment. Gum Arabic, a
natural exudate produced from plants, is widely used traditionally for religious,
cosmetics as well as medical purposes since ages. Although it is well reported for its
biological activities and medical value, no studies have been carried to assess its
anticancer potential. In search of new and novel compounds to target TNBCs
effectively and less toxicity, this study aims to evaluate the anticancer activity of Gum
Arabic extract (GAE) and against breast cancer MDA-MB-231 cell line, a triplenegative human breast cancer cell line, and to elucidate the molecular targets
underlying its mechanism of action. The results revealed that GAE inhibits cell
proliferation in a concentration- and time-dependent manner. The anti-proliferative
effect of GAE was found to be linked to cell cycle arrest at the G1/S phase along with
induction of apoptosis confirmed in the cells as suggested by caspase 3/7 activation
and cleaved caspase 3 and cleaved PARP detection. Cell cycle inhibitory protein
p21WAF1 was increased in GAE treated cells compared to untreated cells while cyclin
D1 and c-myc were downregulated. Furthermore, the study found that Wnt/β-catenin
signaling was markedly inhibited and could induce loss of expression of the canonical
Wnt-directed targets genes cyclin D1, c-myc, and survivin in MDA-MB-231 cells
treated with GAE. In conclusion, GAE inhibits the proliferation of MDA-MD-231
breast cancer cells that is associated with the suppression of Wnt/β-catenin signaling
suggesting that Gum Arabic could be a potential new chemotherapeutic agent against
highly chemoresistant triple negative breast.
Keywords: Gum Arabic, triple-negative breast cancer, apoptosis, cell cycle,
cell cycle arrest, anti-breast cancer agent.
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)Title and Abstract (in Arabic

دراﺳﺔ اﻵﻟﯿﺎت ﻋﻠﻰ اﻟﻤﺴﺘﻮى اﻟﺠﺰﯾﺌﻲ اﻟﺘﻲ ﯾﻘﻮم ﻋﻠﯿﮭﺎ اﻟﻨﺸﺎط اﻟﻤﻀﺎد ﻟﻠﺴﺮطﺎن ﻟﻠﺼﻤﻎ
اﻟﻌﺮﺑﻲ ﻋﻠﻰ ﺧﻼﯾﺎ ﺳﺮطﺎن اﻟﺜﺪي اﻟﺜﻼﺛﻲ اﻟﺴﻠﺒﯿﺔ
اﻟﻤﻠﺨﺺ

ﺳﺮطﺎن اﻟﺜﺪي ﺳﺮﯾﻊ اﻻﻧﺘﺸﺎر ھﻮ اﻟﺴﺒﺐ اﻟﺮﺋﯿﺴﻲ ﻟﻠﻮﻓﯿﺎت اﻟﻤﺮﺗﺒﻄﺔ ﺑﺎﻟﺴﺮطﺎن ﺑﯿﻦ اﻟﻨﺴﺎء ﻓﻲ
ﺟﻤﯿﻊ أﻧﺤﺎء اﻟﻌﺎﻟﻢ .ﺳﺮطﺎن اﻟﺜﺪي اﻟﺜﻼﺛﻲ اﻟﺴﻠﺒﻲ ) (TNBCھﻮ اﻷﻛﺜﺮ ﺧﻄﻮرة ،ﺣﯿﺚ ﯾﻤﺜﻞ 15-
ﻧﻈﺮا ﻷن ﺧﻼﯾﺎ  TNBCﺗﻔﺘﻘﺮ إﻟﻰ اﻟﺘﻌﺒﯿﺮ ﻋﻦ ﻣﺴﺘﻘﺒﻼت
 20%ﻣﻦ ﺟﻤﯿﻊ ﺣﺎﻻت ﺳﺮطﺎن اﻟﺜﺪيً .
ھﺮﻣﻮن اﻻﺳﺘﺮوﺟﯿﻦ ) (ERوﻣﺴﺘﻘﺒﻼت اﻟﺒﺮوﺟﺴﺘﺮون ) (PRوﻣﺴﺘﻘﺒﻼت ﻋﺎﻣﻞ ﻧﻤﻮ اﻟﺒﺸﺮة
اﻟﺒﺸﺮي  ،(HER2) 2ﻓﺈن  TNBCsﻻ ﺗﺴﺘﺠﯿﺐ ﻟﻠﻌﻼج اﻟﮭﺮﻣﻮﻧﻲ وﻏﺎﻟﺒًﺎ ﻣﺎ ﺗﺼﺒﺢ ﺷﺪﯾﺪة
اﻟﻤﻘﺎوﻣﺔ ﻋﻨﺪ ﺗﻌﺮﺿﮭﺎ ﻟﻠﻌﻼج اﻟﻜﯿﻤﯿﺎﺋﻲ اﻟﻤﺴﺘﺨﺪم ﺣﺎﻟﯿﺎ ً ،واﻟﺬي ﯾﻤﺜﻞ ﻋﻘﺒﺔ رﺋﯿﺴﯿﺔ ﻓﻲ ﻋﻼج
 .TNBCﯾﺴﺘﺨﺪم اﻟﺼﻤﻎ اﻟﻌﺮﺑﻲ ،وھﻮ إﻓﺮاز طﺒﯿﻌﻲ ﯾﻨﺘﺞ ﻣﻦ اﻟﻨﺒﺎﺗﺎت ،ﻋﻠﻰ ﻧﻄﺎق واﺳﻊ
ﻟﻸﻏﺮاض اﻟﺪﯾﻨﯿﺔ وﻣﺴﺘﺤﻀﺮات اﻟﺘﺠﻤﯿﻞ وﻛﺬﻟﻚ ﻟﻸﻏﺮاض اﻟﻄﺒﯿﺔ ﻣﻨﺬ اﻟﻌﺼﻮر .ﻋﻠﻰ اﻟﺮﻏﻢ ﻣﻦ
أﻧﮫ ﺗﻢ دراﺳﺔ أﻧﺸﻄﺘﮫ اﻟﺒﯿﻮﻟﻮﺟﯿﺔ وﻗﯿﻤﺘﮫ اﻟﻄﺒﯿﺔ ،إﻻ أﻧﮫ ﻟﻢ ﯾﺘﻢ إﺟﺮاء دراﺳﺎت ﻟﺘﻘﯿﯿﻢ إﻣﻜﺎﻧﺎﺗﮫ اﻟﻤﻀﺎدة
ﻟﻠﺴﺮطﺎن .ﺑﺤﺜًﺎ ﻋﻦ ﻣﺮﻛﺒﺎت ﺟﺪﯾﺪة وﻣﺒﺘﻜﺮة ﻻﺳﺘﮭﺪاف  TNBCsﺑﺸﻜﻞ ﻓﻌﺎل وأﻗﻞ ﺳﻤﯿﺔ ،ﺗﮭﺪف
ھﺬه اﻟﺪراﺳﺔ إﻟﻰ ﺗﻮﺿﯿﺢ اﻟﻨﺸﺎط اﻟﻤﻀﺎد ﻟﻠﺴﺮطﺎن ﻟﻤﺴﺘﺨﻠﺺ اﻟﺼﻤﻎ اﻟﻌﺮﺑﻲ ) (GAEﺿﺪ
ﺳﺮطﺎن اﻟﺜﺪي  ،MDA-MB-231وھﻲ ﺧﻠﯿﺔ ﺳﺮطﺎن اﻟﺜﺪي اﻟﺒﺸﺮي اﻟﺜﻼﺛﯿﺔ اﻟﺴﻠﺒﯿﺔ .ﻟﺘﻮﺿﯿﺢ
اﻷھﺪاف اﻟﺠﺰﯾﺌﯿﺔ اﻟﻜﺎﻣﻨﺔ وراء آﻟﯿﺔ ﻋﻤﻠﮭﺎ .أظﮭﺮت اﻟﻨﺘﺎﺋﺞ أن  GAEﯾﺜﺒﻂ ﺗﻜﺎﺛﺮ اﻟﺨﻼﯾﺎ ﺑﻄﺮﯾﻘﺔ
ﺗﻌﺘﻤﺪ ﻋﻠﻰ اﻟﺘﺮﻛﯿﺰ واﻟﻮﻗﺖ .أظﮭﺮت اﻟﺪراﺳﺔ ان اﻟﺘﺄﺛﯿﺮ اﻟﻤﻀﺎد ﻟﻠﺘﻜﺎﺛﺮ ﻟـ  GAEﻣﺮﺗﺒ ً
ﻄﺎ ﺑﺘﻮﻗﻒ
دورة اﻟﺨﻠﯿﺔ ﻓﻲ ﻣﺮﺣﻠﺔ  G1 / Sﺟﻨﺒًﺎ إﻟﻰ ﺟﻨﺐ ﻣﻊ ﺗﺤﺮﯾﺾ ﻣﻮت اﻟﺨﻼﯾﺎ اﻟﻤﺒﺮﻣﺞ اﻟﻤﺆﻛﺪ ﻓﻲ
اﻟﺨﻼﯾﺎ ﻛﻤﺎ ھﻮ ﻣﻘﺘﺮح ﺑﻮاﺳﻄﺔ ﺗﻨﺸﯿﻂ  caspase 3/7و PARP 3 caspaseاﻟﻤﺸﻘﻮق .ﺗﻤﺖ زﯾﺎدة
اﻟﺒﺮوﺗﯿﻦ اﻟﻤﺜﺒﻂ ﻟﺪورة اﻟﺨﻠﯿﺔ  p21WAFAﻓﻲ اﻟﺨﻼﯾﺎ اﻟﻤﻌﺎﻟﺠﺔ ﺑـ  GAEﻣﻘﺎرﻧﺔ ﺑﺎﻟﺨﻼﯾﺎ ﻏﯿﺮ
اﻟﻤﻌﺎﻟﺠﺔ ﺑﯿﻨﻤﺎ ﺗﻢ ﺗﻘﻠﯿﻞ ﺗﻨﻈﯿﻢ  cyclin D1و  .c-mycﻋﻼوة ﻋﻠﻰ ذﻟﻚ ،أﺛﺒﺘﺖ اﻟﺪراﺳﺔ أن إﺷﺎرات
 Wnt / β-cateninاﻟﺨﻠﻮﯾﺔ ﻗﺪ ﺗﻢ ﺗﺜﺒﯿﻄﮭﺎ ﺑﺸﻜﻞ ﻣﻠﺤﻮظ وﯾﻤﻜﻦ أن ﺗﺆدي إﻟﻰ ﻓﻘﺪان اﻟﺘﻌﺒﯿﺮ ﻋﻦ
ﺟﯿﻨﺎت اﻷھﺪاف اﻟﻤﻮﺟﮭﺔ ﻟـ  cyclin D1 Wntو  c-mycو  survivinﻓﻲ ﺧﻼﯾﺎ MDA-MB-
 231اﻟﻤﻌﺎﻟﺠﺔ ﺑـ  .GAEﻓﻲ اﻟﺨﺘﺎم ،ﯾﻤﻨﻊ  GAEﺗﻜﺎﺛﺮ ﺧﻼﯾﺎ ﺳﺮطﺎن اﻟﺜﺪي MDA-MD-231
اﻟﻤﺮﺗﺒﻂ ﺑﻘﻤﻊ إﺷﺎرات  Wnt / β-cateninﻣﻤﺎ ﯾﺸﯿﺮ إﻟﻰ أن اﻟﺼﻤﻎ اﻟﻌﺮﺑﻲ ﯾﻤﻜﻦ أن ﯾﻜﻮن ﻋﺎﻣﻞ
ﻋﻼج ﻛﯿﻤﯿﺎﺋﻲ ﺟﺪﯾﺪ ﻣﺤﺘﻤﻞ ﺿﺪ اﻟﺜﺪي اﻟﺜﻼﺛﻲ اﻟﺴﻠﺒﻲ اﻟﻤﻘﺎوم ﻟﻸدوﯾﺔ اﻟﻜﯿﻤﯿﺎﺋﯿﺔ.
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ﻣﻔﺎھﯿﻢ اﻟﺒﺤﺚ اﻟﺮﺋﯿﺴﯿﺔ :اﻟﺼﻤﻎ اﻟﻌﺮﺑﻲ ،ﺳﺮطﺎن اﻟﺜﺪي ﺛﻼﺛﻲ اﻟﺴﻠﺒﯿﺔ ،ﻣﻮت اﻟﺨﻼﯾﺎ اﻟﻤﺒﺮﻣﺞ،
دورة ﺣﯿﺎة اﻟﺨﻠﯿﺔ ،إﯾﻘﺎف دورة ﺣﯿﺎة اﻟﺨﻠﯿﺔ ،ﻋﺎﻣﻞ ﻣﻀﺎد ﻟﺴﺮطﺎن اﻟﺜﺪي.
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Chapter 1: Introduction
Cancer
Cancer is a disease which causes a group of abnormal cells to divide
uncontrollably and it is characterized by disregarding the normal rules of cell division
[1]. Cancer is a term that specifically refers to a new cellular growth which has the
ability to spread throughout the body to new areas (metastasize) where they form new
colonies, and infiltrate surrounding tissues [2]. Cancer cells which originate within
tissues, as they grow and divide at an abnormal accelerated rate, are “poorly
differentiated” which have abnormal morphology and lacks the normal tissue
structures, and have irregular membranes, cytoskeletal proteins, and morphology. This
abnormality in cells can be progressive with a slow transition from normal cells to
benign tumors and then malignant tumors [3], [4].
Any tumor can be either benign or malignant. A benign tumor remains
restricted to its original location. It does not invade nearby normal tissue nor spread to
another body sites. In contrast, a malignant tumor has the capability of both invading
nearby normal tissues and spreading throughout the body through the lymphatic or
circulatory systems. Unlike benign tumors, only malignant tumors are referred to as
cancers, due to their ability to invade surrounding tissues and metastasize, which is the
primary cause of cancer morbidity and mortality (Figure 1) [5], [6].

2

Figure 1: The transformation process. Different insults continuously act on cells
leading to transformative alterations in (epi) genetics, chromosomal numbers and
arrangements, and heterotypic interactions which, along the path towards malignancy,
undergo cycles of evolutionary clonal selection leading to the acquisition of cancercompetent traits, the hallmarks of cancer [7].

Hallmarks of cancer
The hallmarks of cancer consist of six biological capabilities obtained during
the development of tumors (Figure 2). The hallmarks establish an organizing principle
for explaining the complexity of neoplastic diseases [7].

Figure 2: Hallmarks of cancer [7].
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1.2.1 Self-sufficiency in growth signals
Normal cells depend on growth signaling of a regulated cell cycle in order to
control proliferation and maintain tissue homeostasis, but in case of cancer, such
balance is disrupted. Currently in cancer cells, the growth and signaling pathways that
control cell proliferation suppress one or more driving alterations within their
compartments giving them a survival edge. Those compartments include growth
ligands, their receptors or the cytosolic signaling molecules [8].
Several types of extracellular matrix receptors (integrins) that are expressed by
cancer cells is switched, so it can favor the receptors that transmit pro-growth signals
[7]. Even if growth signals are present, the cell cycle regulation through regulatory
proteins maintains the division cycles in and keep it in check. Checkpoint disruption
and deregulation of the cell cycle are important for cancer cells to grow [8].
1.2.2 Insensitivity to anti-growth signals
Proliferation is blocked by antigrowth signals, by two mechanisms. Cells are
arrested during the active proliferative cycle and forced out into the quiescent (G0)
state from which they may reemerge on some future occasion when extracellular
signals permit [7]. By disrupting the pRb pathway, E2F transcription factor is released
and hence this gives cell proliferation the capability of rendering cells which can
normally operate along this pathway to become insensitive to antigrowth factors and
block advance through the G1 phase of the cell cycle [7].
1.2.3 Evasion of apoptosis
Apoptosis is a form of programmed cell death that occur in organisms to
eliminate unnecessary or infected cells from the body over the course of development
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or as a result of undergoing cellular stress. Cancer cells are always under constant
stress, such as genomic instability, oncogenic stress, and cellular hypoxia [9].
Although the intrinsic pathway of apoptosis would be normally activated as a response
to these internal apoptotic stimuli, cancer cells can sometimes avoid this cellular
response by disabling the apoptotic pathways [9].
1.2.4 Limitless replicative potential
The maintenance of telomeric DNA underlies the ability of tumors to possess
unlimited replicative potential, one of the hallmarks of cancer. Telomere length and
structure are maintained by the reverse transcriptase telomerase and a multiprotein
telomere complex termed shelterin. Telomerase activity has been elevated in the
majority of tumors. Unlike normal tissues, telomeres are critically shortened in tumors,
hence providing a compelling principle to target the telomerase/telomere pathway for
broad-spectrum cancer therapy [10]. At some point during the course of multistep
tumor progression, evolving premalignant cell populations exhaust their endowment
of allowed doublings and can only complete their tumorigenic agenda by breaching
the mortality barrier and acquiring unlimited replicative potential [7].
1.2.5 Sustained angiogenesis
Malignant tumors often outgrow their blood supply and in order to grow it
should actively recruit vasculature. Angiogenesis is promoted by tumor cells by up
regulating the pathways that promote blood vessel formation such as increased
expression of vascular endothelial and fibroblast growth factors [11].
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1.2.6 Tissue invasion and metastasis
Malignant cells possess key hallmarks, which is uncontrolled growth potentials
and the ability to invade surrounding tissues and metastasize. The degree and timing
of invasion and metastasis may vary due to the genetic and epigenetic heterogeneity
within the tumor. Moreover, it can be associated with further signals from extrinsic
factors, such as those within that particular tumor microenvironment (Figure 3) [5].

Figure 3: Cancer invasion and metastasis. Abnormal cells start proliferated in a noncontrolled manner, forming a primary tumor. Cancer cells invade near tissues; after
that, cancer cells interred the bloodstream and translocated into distant sites, and
develop new colonies [12].

Types of cancer
There are more than 100 different types of cancer. Cancer is named for the
tissue or organ where it originates from. Cancers may also be described by the type of
cell that formed them, such as a squamous or an epithelial cell [2], [13]. From a
histological viewpoint, there are hundreds of several cancers, which are categorized
into five major groups [14]:
▪

Carcinoma is cancer that begins in the skin or in tissues that cover internal
organs [15]. It is identified as a stage 0 cancer, because it is located only in
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the layer of skin where it started. Carcinoma can originate in and spread to
any area throughout the body. Most common types of carcinoma are skin
cancer, and breast cancer [16].
▪

Sarcoma refers to cancer that originates in connective tissues such as bones,
cartilage, and muscle. The most common sarcoma that occurs in young
adults often develops as a painful mass on the bone [14]. Sarcomas are
divided into two main types: bone cancers as well as soft tissue sarcomas.
These are also classified into more than 70 sarcoma subtypes which are
named based on the nearby tissue, the type of cells creating the tumor, or
the affected area of the bone [17].

▪

Leukemia are cancers that begin in the blood forming tissue of the bone
marrow, which is caused by the buildup of huge numbers of abnormal
white blood cells in the bone marrow and blood. As a result, normal blood
cells are crowded out [13]. After, the leukemia cells interrupt the
development of normal cells [18]. There are four common types of
leukemia, which are categorized based on the time of how the disease gets
worse, and on the type of blood cell the cancer starts in [13].

▪

Lymphoma is a wide term used to describe cancer that begins in cells of
the lymphatic system. The two major types are Hodgkin lymphoma and
Non-Hodgkin lymphoma [19]. Non-Hodgkin lymphomas starts when T
cell or B cell (type of white blood cell) becomes abnormal [20].

▪

Melanoma is cancer that begins in cells that become melanocytes, which
are specialized cells that make melanin (the pigment that gives skin its
color) [13]. These abnormal cancerous growths develop when unrepaired
DNA damage to skin cells which is often caused by ultraviolet radiation,
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triggers mutations that direct the skin cells to multiply rapidly to form
malignant tumors [21].
Cancer epidemiology
Cancer is a non-communicable disease (NCDs). The occurrence and mortality
of cancer significantly vary between countries and across cancer types. Cancer
considers as the first leading cause of premature death (i.e., at ages 30–69 years) in 55
countries and the second in 79 countries worldwide [22], [23]. Cancer causes around
1 in every 6 death worldwide, higher than AIDS, tuberculosis, and malaria combined
[24]. According to the International Agency for Research on Cancer (IARC), 18.0
million new cancer cases and 9.5 million cancer-related death (about 26,000 cancer
deaths a day) were recorded worldwide in 2018 [22], [24], [25]. By 2040, it is
estimated that the global burden of cancer will grow to around 30 million new cancer
cases and 16.4 million cancer deaths due to the population's growth, aging and the
increased risks of modifiable factors [24], [25].
In the United Arab Emirates (UAE), cancer is the third leading cause of death
after cardiovascular diseases and injury. In 2017, it was estimated that cancer caused
16% of total NCDs mortality in the UAE [26]. In 2020, according to World Health
Organization (WHO), 4807 new cancer cases and 1896 cancer-related death were
reported [27]. WHO estimated that by 2040, the increase would be almost 300% to
indices 19,067 new cases, whereas mortality would be increased by 380% to occupy
10,014 death cases [25].
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Cancer risk factors
Cancer is a multifactorial disease, as the main leading cause of cancer is not
entirely understood. Many factors can play a role in increasing the risk for cancer
development [22]. These factors are divided into adjustable and nonadjustable factors.
Adjustable risk factors include tobacco consumption and smoking, excess body
weight, unhealthy diet, physical inactivity, exposure to environmental pollutants, and
ultraviolet (UV) radiation [24]. Nonadjustable factors such as inherited genetic
mutations, hormones, and immune conditions. Both adjustable and nonadjustable
factors can interact together or in sequence to initiate or promote cancer growth [27].
Cancer treatment
Current available treatments for cancer include radiotherapy, surgery, and
chemotherapy [28]. Radiotherapy was first used for cancer treatment over 100 years
ago by using crude radium as the radiation source [29]. Radiotherapy must be
performed as a mandatory step in treatment after conventional surgery for an invasive
tumor, regardless of the characteristics of the disease, because it decreases the rate of
local recurrence and by this way, specific mortality [30]. The therapeutic potential of
chemotherapy against cancer is seriously not satisfying enough due to the nonspecific
drug distribution, heterogeneity of cancer, and multidrug resistance (MDR) [28]. In
fact, American Cancer Society’s main objective is to detect for example breast cancer
in its onset stages, and this is an opportunity to cure the disease with relatively simple
surgical procedures [31]. Meanwhile, according to modern cancer therapy, not every
malignant tumor has an available cure. Therefore, treatment needs to be cautiously
chosen to maximize the chance for a cure while providing a maximum quality of life
[32].
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Breast cancer
Breast cancer is a malignant tumor that develops from breast cells. Usually,
breast tumors start from ductal hyperproliferation. It develops into benign tumors or
metastatic carcinomas after constant stimulation of various carcinogenic factors
(Figure 3). These factors result in a series of genetic events that lead to alterations in
proto-oncogenes and tumor suppressor genes [33], [34].
1.7.1 Breast cancer epidemiology
About one in eight women are diagnosed with breast cancer during their
lifetime [35]. According to the American Cancer Society, more than 8 million women
were diagnosed with cancer in 2018. Breast cancer showed to be the most frequent
malignancy diagnosed in women worldwide. It accounts for about 25% of all women
cancer cases, 15% of all women cancer-related deaths, making breast cancer the first
leading cause of cancer-related deaths worldwide [24], [36]. These statistics make
breast cancer a significant public health concern [37]. Despite the great improvement
in early diagnosis and effective treatment in recent years, approximately a third of all
women with breast cancer develop metastatic cancer, which eventually leads to death.
[38], [39]. Previous years showed an increase in survival rate, but sadly survivors have
a higher risk of cancer re-occurrence than those who don’t have prior cancer history
[40]. The 5-year survival depends on the extent of the disease, whether it is “localized”
or “regional. Countries with more-developed health services showed a higher 5-year
survival rate (around 30% higher) compared with developing countries, in addition to
a decrease in the mortality rate. It is estimated that by 2030, the number of breast
cancer incidence will increase between 2.4 million per year to 3.2 million per year
[41].
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1.7.2 Breast cancer in the UAE
In the UAE, breast cancer is the most prevalent cancer among females, with
38.86% of all reported female cancers and the second cause of death among the UAE
women [27], [42]. Breast cancer incidence and mortality in UAE have a lower agestandardized rate than the European countries and the US with almost one decade [43],
[44]. It was reported that 55.8% of all breast cancer cases were in women under 50,
and 21.5% were in women between 30 and 40 [44]. By 2030, It is expected that the
number will double for breast cancer cases in the UAE [25].
1.7.3 Breast cancer risk factors
Several risk factors can increase the risk of developing breast cancer [35].
These risk factors can be divide into intrinsic (unmodifiable) and extrinsic
(modifiable). The unmodifiable are factors that a person cannot control or change,
while the modifiable are factors that a person can handle [45].
1.7.3.1 Non-genetic intrinsic risk factors
Several factors are unmodifiable, including age, gender, reproductive factors,
and endogenous hormone exposure, personal or family history of breast disease. Age
and gender are the most potent risk factor for breast cancer [46]. Being a woman
increases the risk of developing cancer about 100 times more than in men. Age
increases the risk gradually, from rare before 20 to 100 times more by the age of 4555 [47], [48]. Breast cancer cases are primarily diagnosed in women age 55 and older,
and by the age of 90, one-fifth of women are affected [48]. Moreover, personal history
raises the risk of developing breast cancer. Having cancer in one breast increases the
risk of developing new cancer in the second breast or another part of the same breast.
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Besides, breast cancer survivors have a significant risk of developing breast cancer
again [35], [46]. It is well document that having a positive first-degree relative (mother,
sister, or daughter) or two first-degree relatives diagnosed with breast cancer will
increase the risk of developing breast cancer by almost double or 3-fold respectively
[46]. Along with the risks mentioned above, benign proliferative lesions of the
mammary gland and chronic inflammation are also correlated with metastatic breast
cancer and lower survival [45]. The expression of estrogen throughout a woman’s
lifetime has implications in the development of or the protection against breast cancer
[35]. Long exposure duration to higher concentrations of endogenous estrogen
increases the risk of developing breast cancer [47], which usually happens in women
with early menarche (≤ 11 years) or late menopause (55) [34], [47]. Increased risk of
developing breast cancer is also linked to higher testosterone levels in women at
premenopausal and postmenopausal [35], [47].Women who have first birth at a young
age have a lower risk for developing breast cancer. However, getting first birth at
older ages increases the risk of developing breast cancer more than the nulliparous
women [35], [46]. Other unmodifiable factors are race and ethnicity. Breast cancer
prevalence varies with the ethnic difference. Breast cancer is more common among
whites than African- Americans. However, African-American women are more
commonly to develop breast cancer under the age of 45 and have a higher prevalence
of triple-negative breast cancers. Therefore, it is more likely for African-American
women to die from breast cancer at any age. Other races have a lower risk of
developing and dying from breast cancer, such as Asian, Hispanic, and Native
American women [46], [47]. The variance among ethnic groups is estrogen and
progesterone receptor subtypes and status in each group [47].
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1.7.3.2 Extrinsic risk factors
The main extrinsic risk factors are behavioral and lifestyle habits. Modern
lifestyle includes excessive use of alcohol, low physical activity, and consuming a lot
of dietary fat leading to obesity (being overweight). As a result, fat tissues can cause
an increase in estrogen levels in women, which can increase the risk of developing
breast cancer [33]. Exposure to ionizing radiation such as medical radiation treatment
or nuclear explosion increases cancer risk [35], [49]. Moreover, after menopause,
hormone replacement therapy (HRT) increases the risk of breast cancer, chances of
dying from breast cancer, and the probability of getting diagnosed at a late stage [46].
Long-term use of HRT increases the risk of developing breast cancer, 15% in 5 years
and 34% in the case of 10 years [50]. However, the risk is eliminated within five years
after stopping HRT usage. Likewise, oral contraceptive increases the risk slightly, but
it abolished after stopping oral contraceptive usage [46]. Moreover, having no children
or having them at a late age slightly increases the risk [33], whereas becoming pregnant
at an early age or having many pregnancies reduces breast cancer risk [46]. Also,
exposure to chemicals such as organochlorines, dioxins, and organo-chlorine can
increase breast cancer risk as they can lead to oncogenes mutations [47], [49].
1.7.4 Classification of breast cancers
Breast cancer is a heterogeneous disease with specific histological and
biological features. These properties can vary according to the genetic, epigenetic, and
transcriptome changes, which ultimately cause differences in a patient's clinical
behavior, diagnosis, prognosis, and treatment response [51-54]. Today, breast cancer
is classified according to histological type and grade, stage biomarker receptor status,
and gene expression profiling [54], [55], based on histological features into triple-
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negative breast cancer (TNBC), hormone-receptor-positive, and human epidermal
growth factor receptor-2 overexpressing (HER2+) [56]. There are two factors that
determine the appropriate survival outcome in breast cancer: (1) detection of disease
at an early stage with screening mammography, and (2) advances in adjuvant systemic
treatment including hormone therapy, chemotherapy, and HER2-targeted therapy that
eliminates micrometastases after definitive surgery for breast cancer (Table 1) [57].
1.7.4.1 Molecular classification of breast cancers
The molecular classification of cancer helps in identifying the alteration in
gene expression in cancer cells. The molecular classification made considerable
differences in prognosis, medication responses, and clinical outcomes for each cancer
subtype (Table 2) [58]. Besides, identifying the expression alteration plays a role in
selecting the most effective treatment, reducing relapse, or help in designing a specific
selective therapy for each patient [53], [58]. According to various gene expression
analysis, breast cancer is divide into five subtypes; i) luminal A, ii) luminal B, where
estrogen (ER), progesterone receptors (PR) are frequently positive, iii) human
epidermal growth factor receptor 2 overexpression (HER-2 positive) with ER- /PRnegative, iv) basal-like and v) normal breast tissue-like [51], [54]. Clinically, HER2
and basal-like tumors showed the worst aggressive behavior among the five subtypes.
In contrast, basal-like tumors contain one of the most aggressive cancer types, triplenegative breast cancer [55].

Table 1: Description of therapies available to treat breast cancer, the corresponding drugs, and mode of action on the tumor cells [59]
Therapies available Drugs used
Chemotherapy
• Alkylating agents (e.g., Cisplatin and Carboplatin)
• Antimetabolites (e.g., 5-fluorouracil (5-FU), Capecitabine
and Gemcitabine)
• Anti-tumor antibiotics:
1) Anthracyclines such as Doxorubicin and Epirubicin
2) Not anthracyclines
• Topoisomerase inhibitors (e.g., Mitoxantrone)
• Mitotic inhibitors:
1) Taxanes such as Docetaxel and Paclitaxel
2) Vinca alkaloids such as Viblastine
Immunotherapy

• PD-L1 inhibitors (e.g., Atezolizumab)

Endocrine therapy • Tamoxifen Fulvestrant

Target therapy

• Aromatase inhibitors
• Trastuzumab (Herceptin) Pertuzumab Ado- trastuzumab
emtansine Lapatininb
• CDK4/6 inhibitors (e.g. Palbociclib and Ribociclib)
• Everolimus
• Olaparib or Talazoparib
• Alpelisib

• Keep the cell from reproducing by damaging its DNA.
• Interfere with DNA and RNA by acting as a substitute for the normal
building blocks of DNA and RNA.
• Not like antibiotics. They work by changing the DNA inside cancer, keeping
it from growing and multiplying.
• Interfere with topoisomerases.
• They stop cells from dividing to form new cells but can damage cells in all
phases by Keeping enzymes from making proteins.
• Immune checkpoint inhibitors. Help to restore the immune response against
breast cancer cells.
• Drugs that block estrogen receptors, stopping estrogen from fueling breast
cancer cells.
• Lower estrogen levels by stopping estrogen production.
• Monoclonal antibody that acts directly against HER2 protein.
• Blocks the cyclin-dependent kinases (CDKs), particularly CDK4 and CDK6,
on hormone receptor-positive breast cancer cells, stopping cells from
dividing.
• For women who went through menopause and had advanced receptorpositive, HER2 (56) breast cancer. The drug block mTOR.
• For women with BRCA gene mutations. These drugs are PARP inhibitors
• For cancers with PIK3CA gene mutation.
• Is a PIK3CA inhibitor.
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1.7.4.1.1 Triple-negative-tumors
Approximately 60% to 90% of basal-like tumors are triple-negative cases [60].
Triple-negative breast cancer (TNBC), which is the cancer that lack the expression of
progesterone receptor and estrogen receptor (ER) and absence of ERBB2 (HER2)
overexpression and/or gene amplification. TNBC accounts for 15–20% of breast
cancer cases and affects more frequently younger patients around the age of 40 [61],
[62]. TNBC contributes to a large proportion of breast cancer deaths despite its small
proportion among all breast cancers [63].

Table 2: Molecular/intrinsic subtypes of breast cancers [46]
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TNBCs are extremely proliferative and characterized by its aggressive nature
(mostly grade III), often exhibit metastasis to secondary sites such as the brain and
lung, early recurrences, and poor survival prognosis, unique molecular profile, and
lack

of

targeted

therapies

and

develop

consistently

resistance

against

chemotherapeutic agents [62], [64]. Common treatments like hormone therapy and
drugs that target progesterone, estrogen, and HER-2 are ineffective, because the tumor
cells lack the necessary receptors [65], making it one of the most challenging groups
of breast cancers to treat. As a result, chemotherapy using cytotoxic drug that inhibit
cancer cells is mainly used in the treatment of TNBCs [60], [62], [66], [67].
Currently, some targeted therapies were approved for TNBC clinical use,
including poly- ADP ribose polymerase (PARP) inhibitors and bevacizumab – a
monoclonal antibody– (vascular endothelial growth factor (VEGF inhibitor). At the
same time, several other potential targets are under investigation and evaluation [74],
including the receptor for advanced glycation end products (RAGE), which involve in
apoptotic activity in TNBC [68] and Epithelial cell adhesion molecule (EpCAM), a
cell surface molecule, its over-expression associated with proliferation and
malignancy in epithelial cancers [59].
1.7.5 Anticancer drugs from plants
Natural products represent a useful source of active molecules and play a key
role in the drug discovery process [69], [70]. Plants were the first medicinal agents to
treat and prevent an uncountable number of diseases and health conditions [71], [72]
Natural compounds as bioactive ingredients isolated from natural sources (fungi,
plants, and marine life forms) have become one of the primary cancer researchers'
interests [73], [74] which have transformed and improved the field of anticancer
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therapeutics [75]. Nowadays, about 60% of all recent discovered anticancer drugs
derive from natural compounds such as plants or plants ‘derived compounds [76].
However, only 10% of the plants have been studied for different disease treatments
[77].
1.7.5.1 Molecular mechanisms of anti-cancer effects of natural products
Naturally occurring substances demonstrated anti-cancer effects by inhibiting
several stages of carcinogenesis, including initiation, promotion, and progression by
affecting cellular and molecular events [78].
1.7.5.1.1 Apoptosis (programmed cell death)
Apoptosis is a tightly organized multi-step pathway where cells commit to
death. This programmed cell death mechanism is exceptionally fateful through
development. However, it is also essential in adult multicellular organisms’
homeostasis as it eliminates unnecessary, unwanted, and damaged cells [79]. It occurs
in a controlled manner to minimize damage and disruption to neighboring cells.
Critical characteristics of apoptosis include changes in the plasma membrane,
cytoplasmic and nuclear shrinkage, condensation of the nucleus, followed by DNA
fragmentation [80]. During apoptosis, cells become rounded and detach from
surrounding cells due to plasma membrane blebbing. The translocation of
phosphatidylserine (PS) from the inner to the outer side of the plasma membrane is a
dominant apoptosis signal that allows the recognition by phagocytic cells to engulf and
consume apoptotic cells. This process is orchestrated primarily, however not
exclusively, by the cysteine proteases family members who are known as caspases
[81].
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1.7.5.1.2 Cell cycle regulation
Cell proliferation involves the reproduction of a cell to form two daughter cells.
The proliferation process is a tightly regulated by a series of events that ensure a
healthy DNA replication and cell division. The cell cycle occurs through several
sequential phases that are highly regulated by several specific cyclin-dependent
kinases (CDKs) and cyclin proteins. S and M phases consider as the major phases in
the cell cycle. In the S phase, DNA replication and chromosome duplication take place.
While in the M phase, the nuclear division (mitosis) and actual cell division occurs. In
most cells, gap phases occur between each phase and another, like G1 before the S
phase and G2 before the M phase. The purpose of these gaps is to provide additional
time for cells to grow and regulate transitions that control the progression to the next
stage of the cell cycle. G1 phase consider as the initial phase in the cell cycle, as it
determines if the cell will continued division or exit from the cell cycle. Cells go into
prolonged G1 or withdrawal into a non-dividing state called G0 in case of nonstable
growth conditions [82], [83].
In some cases, cells may pause the cell cycle progression to respond to
intracellular or external stimuli. The pause is referred to as a “checkpoint”, which
allows the cell to fix any damaged DNA or acquire a sufficient growth factor level
before transitioning to the next phase. If the cells are not able to repair the DNA
damages, the cell will activate apoptotic-signaling cascades to prevent generating
daughter cells with damaged DNA. Checkpoint is highly crucial in the cell cycle to
maintain genomic stability, preventing carcinogenesis. In most tumors, these
checkpoints are deregulated [83].
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Figure 4: Cell cycle regulation by several specific cyclin-dependent kinases (CDKs)
and cyclins proteins [84]

1.7.5.1.3 DNA damage
Different stresses can alter DNA which results in DNA damages. Stressors
included chemicals, radiations such as UV light, and reactive oxygen species (ROS),
among others. Under normal conditions, cells can repair these damages and maintain
genomic stability [85]. When cells are under stress, they activate several mechanisms
to repair damaged DNA and protect the genetic information, checkpoint proteins
pusses the cell cycle progression to allow the DNA repair. If cells are unable to fix the
damaged DNA, the cell activates apoptosis pathway to eliminate potentially dangerous
mutations [86]. Cancer can result due to the accumulation of non-repaired damaged
DNA in these stressed cells. Changes in typical DNA sequence can alter several genes,
including proto-oncogenes and tumor suppressor genes.
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Most cancer tumors have mutations in DNA damage repair and signaling
pathways that contribute to their aggressive phenotype [85],[87]. Moreover, particular
DNA repair pathways enable cancer cells to survive DNA damage induced by
chemotherapeutic treatments, making them resistant to such drugs [88].
1.7.5.2 Review on anti-cancer activity of natural compounds derived from plants
The anticancer potential of plant-derived natural compounds (such as luteolin
and curcumin) has been associated to their capability to target multiple impairment
regulatory mechanisms of signaling pathways (such as mitogen-activated protein
kinase (MAPK) and Hedgehog) causing suppression of proliferation, inflammation,
cell growth, migration, angiogenesis, epithelial-mesenchymal transition (EMT) and
metastasis, and activation of apoptosis in TNBCs [69]. Plant-derived compounds,
including the epipodophyllotoxin analogues and the vinca bisindole alkaloids have
been among the most extensively used cancer chemotherapeutics available, and
interest in these compounds and other natural products to defeat cancer is increasing
[89].
Gallic acid isolated from Phaleria macrocarpa showed anti-cancer effect in
several human cancer cell lines including, lung cancer, leukemia, and colon
adenocarcinoma cell lines and prevents malignancy transformation cancer
development [90]. Moreover, in breast cancer, P. macrocarpa showed antiproliferative, anti-angiogenic, and pro-apoptotic effects. Apoptosis induced by P.
macrocarpa was through intrinsic apoptotic signaling pathway by caspase-9
activation, downregulation of B-cell lymphoma 2 protein (Bcl-2), and upregulation of
Bcl-2 associated X proteins (BAX), followed by further activation of caspases 3, 6, 7,
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and finally activating DNAase to cause DNA fragmentation, thus inducing apoptosis
[91].
Curcumin, the principal curcuminoid of turmeric (Curcuma longa),
emonstrated anti-cancer activity in several studies. Curcumin exerts its anticancer
action by targeting multiple pathways (such as MAPK and NF-κB pathways) and
modifies various target proteins and genes including growth factors and their receptors
(PDGF, EGF, VEGF), cell surface adhesion molecules (E-cadherin, β-catenin), and
protein kinases (CDKs, EGFR, PKC, p38 MAPK) [92]. Curcumin suppresses cell
growth, migration, and proliferation. It also promotes apoptosis and inhibits
angiogenesis, invasion, and metastasis in cancers through the modulation of some
molecular targets. Curcumin treatment sufficiently reduced cell proliferation and
promoted apoptosis in vitro via the modification of the EGFR-MAPK signaling, as
indicated by curcumin treatment-associated reduce in the levels of phosphorylated
EGFR and ERK1/2 [93]. In breast cancer cell line (MCF-7), curcumin showed
cytotoxicity and anti-proliferation activity through increased caspase 3/9 activity and
induction of apoptosis, downregulation of p21 and upregulating the PTEN/Akt
signaling pathway [94].
In a study done by Solowey et al. [95] Urtica membranacea (Urticaceae),
Artemesia monosperma (Asteraceae), and Origanum dayi post (Labiatae) showed
anticancer activity against several human tumor cells and primary tumor cultures [95].
U. membranacea and A. monosperma showed to induce apoptosis, while O. dayi
showed to activate the caspase-3-independent mechanism [95].
Catharanthus roseus contain vinca alkaloids, vinblastine, and vincristine, the
first agents to advance into clinical use. It showed anticancer activity in leukemias,
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lymphomas, advanced testicular cancer, breast and lung cancers, and Kaposi’s
sarcoma.
Paclitaxel is a chemotherapy drug produced initially from the bark of the
Pacific yew, Taxus brevifolia Nutt. Paclitaxel is significantly active against ovarian
cancer, advanced breast cancer, small and non-small cell lung cancer [96].
Leaves of Azadirachta indica (Neem) showed anticancer activity on prostate
cancer cells (PC- 3). It induces cell death by apoptosis, resulting in increased DNA
fragmentation and a decrease in cell viability [97]. The flowers of Neem also showed
some chemopreventive agents effective in inhibiting liver and mammary gland
carcinogenesis in rats [97].
Hedyotis diffusa, contains Methyl anthraquinonesare, the active component
responsible for inducing apoptosis in many cancer types. In breast cancer cell line
MCF-7, cells were arrested at the S phase, and apoptosis was activated via caspase4/Ca2+/calpain pathway. H. diffusa also showed an anti-cancer effect in cervical,
colorectal cancer, and Hela cells [90].
Lycopene, which is found widely in fruits and vegetables, exhibits anticarcinogenic, and chemoprevention properties in vitro and in vivo models. The
mechanism of action occurred by changes in antioxidant and phase II detoxifying
enzymes by regulating the nuclear factor E2-related factor 2-antioxidant response
element (Nrf2-ARE) system. This induces cell cycle arrest at the G0/G1 phase and
downregulation of growth factor (PDGF, VEGF, and IGF)- by regulating cyclin D1
and the PI3K/AKT/PKB and Ras/RAF/MAPK signaling pathways [92], [98].
Lycopene showed promising anticancer activity in prostate, breast, gastric, colorectal,
liver, renal, bladder, and lung cancer [98]. In the US, Lycopene has entered Phase II
clinical trials to prevent and treat prostate cancer [92].
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Protopanaxadiol and protopanaxatriol were obtained from Asian ginseng.
Protopanaxadiol induces cancer cell apoptosis and inhibits proliferation by targeting
the Wnt/β-catenin signaling pathway, down-regulating of Akt activity, and inhibiting
P-glycoprotein (P-gp) [92]. A mixture of protopanaxadiol and protopanaxatriol
(PandimexTM) has been approved conditionally in China for the treatment of
advanced cancers of the breast, colon- rectum, lung, and pancreas. It is ongoing in
Phase I clinical trial in the US for advanced lung, gastric, breast, and pancreatic cancers
combined with paclitaxel or alone [92].
1.7.5.3 Gum Arabic
Acacia gum (Figure 5A), known as Gum Arabic (GA), is an edible air-dried
gummy exudate secreted by the hardened sap (Figure 5B) of various acacia tree species
[99]. Acacia senegal and Acacia seyal (family Leguminosae) are the only two species
of Acacia gums authorized by Food and Agriculture Organization (FAO) in 1999 and
recognized as safe by the Food and Drug Administration (FDA) [100]. The gum is
produced by the Acacia tree’s trunk or branches due to stress conditions as heat,
drought, insects and mold infections, injury, or amputation [101]. Acacia trees are
natives to the barren areas of the sub-saharian zone, from Senegal to East Africa, and
beyond to India and Pakistan [102]. It also found in Arabian Peninsula, such as Oman
[103].
Sudan is considered the largest producer, followed by Chad and Nigeria.
Together they produce nearly 95% of all GA exported to the worldwide market [101],
[102]. It is shipped as a primary product to industrial countries, mainly Western Europe
and the US [104].
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Acacia seyal gum is a natural, nontoxic hydrocolloid complex [102], with low
stickiness and viscosity, utterly soluble in want without any taste or odor (Figure 5C)
[105].

Chemically,

Acacia

seyal

gum

(Asey)

is

found

in

nature

as

heteropolysaccharide and glucuronic acid residues [106]. It is composed of 37–44%
D-galactose, L- 33–48% arabinose, 2–3% L-rhamnose, 7–13% D-glucuronic acid,
and 6%4-O-methyl-D-glucuronic acid, with a small fraction of proteins 1%, and 4%
of minerals consisting of a complex mixture of potassium, calcium and magnesium
salts [106], [107]. The fractionation of A. seyal gum by hydrophobic interaction
chromatography (HIC) and size exclusion chromatography (SEC) separated it into
three fractions, which were specific as arabinogalactan (AG), arabinogalactan-protein
(AGP), and glycoprotein (GP) [106], [108].

Figure 5: Acacia Gum Arabic. (A) Acacia trees in a savannah of Africa [109]. (B)
Gum Arabic hardened sap [110]. (C) Gum Arabic exudates [111].
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The variance in gum's physical, biochemical composition, and molecular
characteristics depend on a number of factors such as Acacia species trees age,
location, weather conditions, and the way of tapping. Moreover, the post-harvesting
proceeding includes storage situation, maturation period, filtration, high-pressure
homogenization, spray drying, irradiation, or heat treating affect the gums
characteristics [112]. Due to these exceptional physical and chemical functional
properties, the gum was employed in a variety of applications such as food,
pharmaceutical, lithography, textile, cosmetics, and other industrial applications [102],
[107], [105]. It is an excellent emulsifier, film former, thickener, flocculant, and
surface-coating agent, food stabilizer with E-code E414. It is also used to produce
drinks, candy, flavor encapsulations, bakery products, and brewing [102].
In the medical field, GA was demonstrated to effectively treat diarrhea,
dysentery, and wounds [113]. Besides, recent studies highlighted the antioxidant,
cytoprotective, nephroprotective, hepatoprotective, antiulcer, immunomodulatory,
antibacterial, antimalarial [113-115], and has a role in the metabolism of lipids
reducing body mass index (BMI) [116], [117]. It shows a positive effect in the
treatment of several degenerative diseases such as chronic kidney disease [104], [116],
type 2 Diabetes mellitus (DM) [118], [119], cardiovascular and gastrointestinal
disorder [120]. Moreover, GA shows good use as a nanoparticle carrier for drug
delivery [99], [120]. However, very few studies focused on the anti-cancer activity of
GA and its mechanism, and only one study was done on breast cancer cells with the
use of stem barks of Acacia seyal GA [121], and no study, to the best of our knowledge,
test the anti-cancer effect of the dried gummy exudate.

26
1.7.5.4 Safety of Gum Arabic
FDA recognized Gum Arabica as one of the safest nutritional fibers [122], and
they confirmed that it is safe as a food supplement. In addition, GA was approved as
the safest feed additives from the FAO/WHO. Codex Alimentarius Committee
(INS414) and the European Union (E414) approved the use of Gum Arabic in food
[123].
Hypothesis
Gum Arabic from Acacia sp. exerts anti-cancer activity against triple-negative
breast cancer cells MDA-MB-231 through modulating the cell cycle and inducing the
apoptosis pathway.
Objectives of the study
Overall objective of this study is to investigate the potential molecular
mechanisms underlying the anti-cancer activity of Gum Arabic from Acacia sp. in
triple-negative breast cancer.
A. To evaluate the anti-cancer effect of Gum Arabic extract against selected human

cancer cell lines

The study will test the anti-cancer effect of Gum Arabic extract on selected
human cancer cell lines (breast cancer cells MDA-MB-231, MCF-7, Hs578T). The
effect of Gum Arabic extract will be tested on cell viability using different cell-based
assays. Increasing concentrations of Gum Arabic extract will be tested on each cell
line for different period of time points.
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B. To investigate the possible mechanism(s) of action of growth-inhibitory effect

induced by Gum Arabic extract

In this objective, the aim is to study the mechanism(s) of actions by which the
Acacia sp. gum extract (commonly known as Gum Arabic) exerts its growth inhibitory
effect in triple-negative breast cancer cells. To approach this, apoptosis, colony
formation assay, and cell cycle will be evaluated in vitro upon exposure to increasing
concentrations of Gum Arabic extract at different time points.
C. To identify the biochemical events and downstream biomarkers associated with

the cell's response to the anti-cancer effect of Gum Arabic extract

Because most anticancer agents are known to alter gene expression, the study
will examine the effects of the Acacia sp. Gum extract on the expression of pathways
(survival, proliferation) - specific genes in triple-negative breast cancer cell line using
Western blot.
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Chapter 2: Materials and Methods

Preparation of Gum Arabic extract
5.154 g of GA was finely ground and kept in 200 mL of bench ethanol for three
days. The mixture was filtered, and the filtrate was evaporated under a vacuum to yield
1.580 g of fluffy beige solid. Gum Arabic stock solution (mg/mL) was prepared by
dissolving GA in DMSO. Aliquots were stored at - 20°C until later use.
Cells culture reagents, and antibodies
Human breast cancer cells MDA-MB-231(basal-like) and MCF-7 (luminal A)
were maintained in Dulbecco Minimal Essential Medium (DMEM) (Hyclone,
Cramlington, UK). The medium was supplemented with 10% fetal bovine serum
(FBS) (Hyclone, Cramlington, UK) and antibiotics (100 U/ml penicillin/streptomycin)
(Hyclone, Cramlington, UK). Cells were maintained at 37°C under a humidified
atmosphere containing 5% CO2. Cells were monitored daily under EVOS XL Core
Cell Imaging System (Life Technologies), and media was changed when necessary.
Cells were passaged using phosphate buffer saline solution (PBS) for washing the cells
and then 0.25% trypsin/EDTA (Gibco/Invitrogen) for 3-5 minutes at 37°C to allow
cell to detach, then neutralized with 1:1 ratio of media and adjust the final volume with
the growth medium. For each experiment, cells were counted and then seeded at
desired density according to the assay type.
For Western blot analysis, antibody to cyclin B1 (05-373), Cyclin D1 (041151) cyclin A1 (2477862), p21 (05-655), and c-myc (AB3252) were obtained from
Millipore (Millipore, Hayward, CA, USA). Antibodies to β-catenin (sc-7963), β-actinHRP (sc-47778), goat anti-mouse IgG- HRP (sc-2005), and goat anti-rabbit IgG-HRP
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(sc-23575, were obtained from Santa Cruz Biotechnology, Inc (USA). Antibodies to
cleaved PARP (Ab4830) were obtained from Abcam (Abcam, Cambridge, UK).
Antibodies to survivin (2803), Anti-rabbit (7074p2) were obtained from Cell
Signaling.
Measurement of cellular viability
To measure cell viability in vitro, all cells were seeded in triplicate in 96-well
plates at a density of 5 x 103cells per well for MDA-MB-231 and Hs578t cells and 7 x
103 cells per well for MCF-7 in 100 𝜇L of culture medium. Twenty-four hours after
the seeding, cells were treated with increasing AGE concentrations (20, 30, 50, 70,100
𝜇g/mL) or an equivalent volume of vehicle (DMSO) for control cells and incubated
for another 24, 48, and 72 hrs. Cell morphological changes were observed at the
indicated time points and imaged by EVOS XL Core Cell Imaging System (Life
Technologies). After treatment, cell viability was determined using a CellTiter-Glo
Luminescent cell viability assay (Promega Corporation, Madison, USA). In this assay,
CellTiter-Glo measures the amount of ATP signaling, which indicates the
metabolically active cell. Briefly, at each time point, the media was removed by
aspiration from each well; a 1:1 ratio of new media and CellTiter-Glo reagent were
added to each well. The plate was then incubated on gentle shaking at room
temperature for 2 minutes. After that, the plate was incubated for additional 10 minutes
at room temperature. Luminescence was measured using the GloMax® Explorer
Multimode Detection System. Data was provided as proportional viability (%) by
equating the data for treated cells to untreated cells, which is assumed to be 100%. All
experiments were performed in triplicate. The results are representative of an average
of at least three independent experiments. Cell viability was calculated as follow: %
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of cell viability = (luminescence value for treatment / luminescence value for control)
* 100. The results were plotted against the range of GAE concentrations in Excel.
Measurement of caspase 3/7 activity
Caspase 3/7 activity was measured using a luminescent caspase-Glo 3/7 assay
kit (Promega Corporation, Madison, USA) following the manufacturer’s instructions.
Briefly, MDA-MB-231 cells (5 x 103 in each 96 well plate) were treated with indicated
concentrations of GAE (50, 70, 100 μg/mL) or an equal volume of vehicle (DMSO)
as a control for 24 and 48. To measure caspase 3/7 activity, we added a 1:1 ratio
volume of Caspase-Glo® 3/7 reagents to each well of a 96-well plate. Then covered
and mixed in an orbital shaker for 10 minutes at room temperature. Luminescent signal
was measured as described above, and the relative caspase 3/7 activity was normalized
to the number of viable cells per well. Caspase 3/7 activity was calculated and
expressed as fold of induction compared to the control.
Colony formation assay
MDA-MB-231 cells were seeded in 6-well plates at a density of 200 cells/well.
Cells were allowed to grow and form colonies for ten days. On day 10, cells were
refreshed with frsh media containing the indicated concentrations of AGE or an equal
volume of vehicle (DMSO) then allowed to grow for additional 7 days. At the end of
the experiment, plates were washed two times with PBS, cells were fixed for 15 min
with 4% formalin, and then stained with 0.01% crystal violet for 30 min.
In another setting, MDA-MB-231 cells were seeded in 6-well plates at a
density of 2,000 cells/well. After 24 hrs incubation, cells were treated with indicated
concentrations of GAE (30, 50, 70, 100 μg/ml) or an equal vehicle volume (DMSO).
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Seven days later, plates were washed twice with PBS, fixed for 15 min with 4%
formalin, and stained with 0.01% crystal violet for 30 min.
Cell cycle analysis
The cell cycle distribution analysis in control and GAE-treated MDA-MB-231
cells was performed with the Muse™ Cell Analyzer (Millipore, Hayward, CA, USA)
using the Muse™ Cell Cycle Kit (Millipore, Hayward, CA, USA) according to the
manufacturer’s instructions. Briefly, cells (3x105) grown onto 6-well plates were
treated with GAE indicated concentrations of GAE for 48 hrs. Cells were then
collected by trypsinization washed in 1X PBS and fixed in ice-cold 70% ethanol (1:1)
in - 20°C, at least 3 hrs before staining. To prepare cells for staining, cells were washed
off from the ethanol by several wash/centrifugation steps. After that, the Muse cell
cycle test reagent was added to each test tube conating the cell pellet. Cells were
incubated for 30 min at room temperature in the dark. After staining, the cells were
processed for cell cycle analysis. Percentage of cells in G0/G1, S and G2/M phases
were determined using the FlowJo software.
Cell lysate preparation
MDA-MB-231 Cells (1.8 × 106) were treated with GAE (50, 70, 100 μg/ml) or
vehicle (DMSO) for 48 hrs. Then, cells were washed twice with ice-cold PBS, scraped,
pelleted, lysed with sonication in radioimmunoprecipitation assay (RIPA) lysis buffer
(Pierce) supplemented with protease inhibitor cocktail (Roche) and phosphatase
inhibitor (Roche). After incubation for 30 min on ice, cell lysates were centrifuged at
14,000 rpm at 4°C for 20 min. The supernatants were quantified for protein
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concentration using the BCA protein assay kit (Thermo Scientific), and the lysates
were adjusted with lysis buffer. The supernatants were aliquoted and stored at - 80°C.
Western blotting analysis
Equal amounts of cell lysates (15 μg) were electrophoresed through 6-15%
sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) gels along
with PageRuler Plus Prestained Protein Ladder (Thermo Scientific). Proteins were
transferred onto polyvinylidene fluoride PVDF membranes (Millipore) and the
membranes were then blocked in 5% non-fat skim milk prepared in TBST (Trisbuffered saline with 0.05% Tween 20) for one hour at room temperature. Incubation
with specific diluted primary antibodies was performed in blocking buffer overnight
at 4°C. Horseradish peroxidase-conjugated anti-IgG was used as a secondary antibody.
Immunoreactive bands were detected by enhanced chemiluminescence ECL/
SuperSignal West Femto chemiluminescent substrate (Thermo Scientific). When
needed, membranes were stripped in Restore western blot stripping buffer (Thermo
Scientific) according to the manufacturer’s instructions.
Statistical analysis
The data are expressed as the mean ± standard error of the mean ±
standard error of the mean (SEM), and are derived from at least three
independent experiments, unless specified otherwise. Student’s t-test was
used for comparison of two groups. The statistically significant difference
was set at p values of * 0.05, ** < 0.005, *** < 0.001 between control and
treated groups.
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Chapter 3: Results
GAE decreases cell viability of estrogen positive and negative breast cancer
cells
The study started by investigated the anti-breast cancer potential of GAE on
different breast cancer cell lines (MDA-MB-231, Hs578T and MCF-7) using the
CellTiter-Glo® assay. Cells were seeded in triplicates into 96-wells plates and treated
with increasing GAE concentrations for 24, 48 and 72 hrs, and then cell viability was
measured. As shown in Figure 6, GAE treatment led to significant decrease in cellular
proliferation in a concentration and time-dependent manner in all three breast cancer
cell lines in relative to vehicle control (DMSO). The response of the three cell lines to
the GAE treatment showed clear sensitivity to AGE. Notably, the inhibitory effect of
GAE in MDA-MB-231 and Hs567T cells was comparable to or greater than that in
MCF-7, indicating that GAE may be an effective cytotoxic agent against TNBC. More
cell viability reduction was detected in MDA-MB-231 and Hs578T cells at higher
concentrations (70 and 100 µg/mL), which implies a higher sensitivity of both cell
lines to GAE when used at high concentrations. The estimated IC50 (the concentration
that leads to 50% inhibition) value for MDA-MB-231 cells and Hs578T were
approximately 75 μg/mL at 48 hrs with less than 20% cell viability observed at higher
concentration used (100 μg/mL) (Table 3). In contrast, the estimated IC50 of MCF-7
cells was ~100 μg/mL at 48 hrs. Since MCF-7 and MDA-MB-231 exhibited
comparable sensitivity, the study also conclude that estrogen receptor expression does
not affect the GAE-induced growth inhibition in human breast cancer cells.
Collectively, these data indicate that GAE exerts an anti-breast cancer effect.
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Table 3: Molecular characteristics of the breast cancer cell lines and the estimated IC50
values of GAE after 48 hrs
Cell lines

p53 status

ER-α

Estimated IC50
(µg/mL)

MDA-MB-231

mutant

negative

~75

MCF-7

wild-type

positive

~100

Hs578T

mutant

negative

~75

Figure 6: Growth inhibitory effect of GAE. (A) MDA-MB-231, (B) MCF-7, and (C)
Hs578T cell growth determined by cell viability assay. Exponentially growing cells of
the three breast cancer cell lines were cultured in 96 well plated and treated with and
without the indicated concentrations of GAE for 24, 48 and 72 hrs. The statistically
significant difference was set at p values of * 0.05, ** < 0.005, *** < 0.001 between
control and treated groups.
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Figure 6: Growth inhibitory effect of GAE. (A) MDA-MB-231, (B) MCF-7, and (C)
Hs578T cell growth determined by cell viability assay. Exponentially growing cells of
the three breast cancer cell lines were cultured in 96 well plated and treated with and
without the indicated concentrations of GAE for 24, 48 and 72 hrs. The statistically
significant difference was set at p values of * 0.05, ** < 0.005, *** < 0.001 between
control and treated groups. (continued)
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The study further investigated the mechanisms by which GAE exerts its
anti-cancer activity on the highly proliferative and invasive Estrogen Receptor
(ER)-negative, mutant p53 breast cancer cell line MDA-MB-231.
GAE induces morphological changes in breast cancer cells MDA-MB-231
The examined treatment revealed any morphological changes during the
exposure times of the MDA-MB-231 to GAE. For that, the morphology of the
treated cells was monitored overtimes. As shown in Figure 7, untreated MDA-MB231 cells (control) remained healthy and maintained their original morphology,
appeared elongated-spindle shape, adherent, and maintain cell-to cell contact
throughout the treatment periods, indicating a regular rate of proliferation (Figure
7). In contrast, treated MDA-MB-231 cells underwent morphological alterations
in concentration and time-dependent manner. Cells lost their original shape starting
from 24 hrs at high concentrations (70, 100 μg/mL) of GAE treatment. At low
concentrations treatment after 48 hrs, cells lost their elongated-spindle morphology
with long and fine membrane extensions, cells looked enlarged and flattened
compared to untreated cells and starts to loose cell-to cell contact started from 50
μg/mL. At higher concentrations (50, 70,100 μg/mL) showed an apparent
reduction of cell size (cell shrinkage) and number, and membrane blabbing, with
floating cells (dead), which were more observed when the incubation time
extended to 72 hrs. All these observed morphological changes were typical signs
associated with cell death; possibly through apoptosis.

Figure 7: Representative micrographs of the cellular morphology of MDA-MB-231 treated with increasing concentrations of GAE after 48 hrs. Cells were
viewed using EVOS XL Core Cell Imaging System (Life Technologies). Magnification: 40X. The white dashed-arrows show dying cells, the yellow arrows
show elongated-spindle shape cells, and the white arrows show flattened enlarged cells.
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GAE reduces and inhibits MDA-MB-231 colony formation
To further confirm the anti-cancer effect of GAE on human breast cancer cells
MDA-MB-231 cells, long-term inhibitory effects of GAE, a 14-days colony formation
assay was carried out. Results showed that GAE could reduce the clonogenic ability
of MDA-MB-231, from concentration as low as 30 μg/ml. In addition, no colonies
were formed at concentrations higher than 50 μg/ml (Figure 8A).

Figure 8: Colony formation assay. The figures show a clear reduction in colony
formation in MDA-MB-231 cell treated with different concentration of GAE (A) a 14days colony formation assay on MDA-MB-231 treated on day 10 with the indicated
concentrations of GAE (B) Effect of increasing concentrations of GAE on MDA-MB231 cells ability to form colonies.
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To test the direct effect of GAE on colongenic ability of MDA-MB-231 cells,
cells were treated with increasing concentrations of GAE. Results revealed that GAE
treatment GAE reduces colony formation of MDA-Mb-231 cells in a concentrationand –time-dependent manner (Figure 8B). At concentration > 50 µg/mL, a clear
decline trend was observed in the number of colonies compared with the untreated
groups (control), with greater effect seen at 70 and 100 µg/mL. Taken together, these
results confirm the growth inhibitory effect of GAE on MDA-MB-231 cells.
GAE induces G1/S arrest in breast cancer cells
To investigate the mechanism(s) underlying the GAE growth inhibitory
activity on breast cancer cells, the effect of GAE on cell cycle progression was
examined. To this end, MDA-MB-231 cells were treated with the indicated
concentrations of GAE for 48 hrs and then followed by performing cell cycle analysis.
The results showed that treating the cells with AGE caused significant inhibition of
cell cycle progression in MDA-MB-231 cells at 48 hrs leading to an increase in the G1
population. The G1 cells population rose from 44% ± 1.9 in control cells to 50% ±
1.7, 50% ± 2.2 and 48% ± 0.95 in cells treated for 48 hrs with 20, 30 and 50 μg/mL
GAE (Figure 9 A, B), respectively.
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A

Figure 9: GAE treatment induces G1/S arrest in MDA-MB-231 cells. MDA-MB 231
cells were treated with GAE at the indicated concentrations for 48 hrs, and then
analyzed with Muse TM Cell Analyzer as described in Materials and Methods. (A)
Cell cycle distribution analysis of GAE-induced G1/S cell-cycle arrest. (B)
Percentages of cell populations in each phase of cell cycle. The statistically significant
difference was set at p values of *< 0.05 between control and treated groups.
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GAE alters the expression of cell cycle regulatory proteins
Several cell cycle regulatory proteins known to regulate cellular proliferation.
Next, the study investigated, by western blotting, the effect of GAE on selected
proteins know to regulate cellular proliferation. Cyclin D1 is known to be essential for
cell cycle progression [124]. Cyclin D1 overexpression occurs in many types of human
cancer. Cyclin D1 was reported to shorten the G1 phase of cell cycle, and therefore,
inhibition of this protein results in blocking G1-S transition [125]. As shown in Figure
10, cyclin D1 protein level decreased upon the treatment with GAE in a dosedependent manner after 48 hrs. Further, other proteins involved in cell cycle regulation
were examined, cyclin A1 and cyclin B1. Cyclin A1 is essential in S and G2/M phases.
Dysregulation in cyclin A1is implicated in carcinogenesis, progression, and metastasis
of many solid tumors types [126]. Cyclin B1 plays a role in cell transition from the G2
phase to mitosis (M phase), and it is usually overexpressed in primary breast cancer
cells and cancer cell lines [127]. As shown in Figure 10, both cyclins A1 and B1
proteins were down-regulated after 48 hrs in MDA-MB-231 cells in response to GAE
treatment in a dose-dependent manner. Notably, all cyclins D1, A1 and cyclin B1
protein levels were almost unmeasurable with high concentrations of GAE (70 and
100 μg/mL). These results confirm that GAE induces cell cycle arrest, suggesting that
it could be one of the mechanisms by which GAE exerts its anti- cancer activity against
MDA-MB-231 cells.
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Figure 10: GAE alters the expression of several proteins involved in cell cycle
progression. MDA-MB-231 cells were treated with vehicle or increasing
concentrations of GAE (50, 70, and 100 µg/mL) for 48 hrs, then the proteins levels of
cyclins (A) D1, (B) A1, and (C) B1 were examined by Western blotting. β-actin was
used as loading control.

GAE inhibits cell proliferation, downregulates c-myc and up-regulates
p21WAF1 in breast cancer cells MDA-MB-231
c-myc overexpression stimulates cell progression, whereas the downregulation or inactivation of this protein decreases cell proliferation or lead to growth
arrest [128]. c-myc protein was reported to controls G1-S transition through activating
downstream targets and inhibition of cyclin-dependent kinase (Cdk) inhibitor p21WAF1
[129]. p21WAF1 CDK inhibitor acts as tumor suppressor protein by inhibiting cell cycle
progression during G1 and S phases transition [130]. The expression of p21WAF1 was
checked the to determine whether the growth inhibition was mediated through
induction of p21WAF1. The results shown in Figure 11 demonstrate a significant
increase of p21WAF1 protein at concentrations of 50 and 70 μg/mL. However, the
p21WAF1 protein level was abolished in cells treated with 100 μg/mL of GAE.
Therefore, GAE inhibits breast cancer cells by inhibiting c-myc protein expression and
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inducting of p21WAF1 protein expression independent of p53 activity as tumor
suppressor protein in these cells.

Figure 11: GAE alters the expression of regulatory proteins involve in cell
proliferation. MDA-MB-231 cells were treated with vehicle or increasing
concentrations of GAE (50, 70, and 100 µg/mL) for 48 hrs, then the proteins levels of
c-myc (A) and p21WAF1 (B) were examined by Western blotting. β-actin was used as
loading control.

GAE triggers survivin down-regulation in breast cancer cells MDA-MB-231
Survivin a cancer anti-apoptotic marker belongs to the family of inhibitor of
apoptosis proteins (IAP). Survivin plays a crucial role in regulating cell division,
inhibiting apoptosis, and promote invasion and metastasis [131]. Survivin
overexpression was reported in most human cancers, including breast cancer [132],
which is implicated in cell cycle arrest at G2/M and apoptosis inhibition. In contrast,
decreases in survivin expression results in apoptosis. It was reported that survivin
suppresses apoptosis by preventing the activation of caspase-3 and caspase-7 or
interacting with cyclin-dependent kinase (CDK)-4 and CDK-2 to avoid the activation
of apoptotic signaling pathways [131]. Therefore, the possible role of survivin in GAEinduced cell cycle arrest and apoptosis was examined. Toward this, the expression of
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survivin in response to increasing concentrations of GAE after 48 hrs of treatment was
analyzed, by Western blotting. Interestingly, survivin showed a differential effect by
GAE on MDA-MB-231 cells (Figure 12). A low concentration of GAE led to an
increase in the level of survivin, which might conferre resistance to cell death to this
population of cells. However, higher concentrations of GAE result in a vast decrease
in surviving protein expression that might suggest its role in inducing cell death.
Therefore, GAE targets one of the important breast cancer oncoproteins survivin in
basal-like breast cancer cells.

Figure 12: Differential regulation of survivin expression by GAE in MDA-MB-231
cells. Western blot analysis shows a differential effect on survivin expression by
different concentrations of GAE in MDA-MB-231 cells. Whole-cell proteins were
extracted from GAE or vehicle (DMSO)-treated cells and subjected to Western blot
analysis. β-actin was used as loading control.

GAE down-regulates β-catenin protein level in breast cancer cells MDA-MB231
Wnt/ β-catenin pathway has a well-established role in tumorigenesis.
Abnormal expression of Wnt/β-catenin signaling was proven to contribute to the
initiation, progression, and metastasis in various human cancers, including breast
cancer [133], [134]. Indeed, targeting Wnt/ β-catenin signaling pathway is of great
significance in the treatment of cancer. Toward this, Western blotting was used to
measure the protein level of β-catenin in response to increasing GAE concentrations
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after 48 hrs. The results showed that GAE caused a massive decrease in β-catenin
protein expression in human breast cancer MDA-MB-231 cells compared to DMSOtreated (control) cells (Figure 13). Notably, the expression of β-catenin totally
vanished at 100 µg/mL. These data clearly indicate that GAE treatment resulted in the
inhibition of β-catenin signaling in human breast cancer cells. To confirm the GAEdown regulation effect on β -catenin signaling, the study sought whether GAE
treatment can affect β-catenin target genes. β-catenin is responsible for regulating
downstream genes such as c-myc, cyclin D1 and survivin [133]. The results showed
down-regulation of c-myc, cyclin D1, and survivin protein expression. These results
indicate that GAE treatment downregulates β-catenin and its target genes in human
breast cancer cells.

Figure 13: GAE inhibits the β-catenin signaling pathway. Concentration-dependent
decrease of β- Catenin protein in GAE-treated MDA-MB-231 cells. Cells were treated
with vehicle (DMSO) or indicated concentrations of GAE for 48 hrs, then whole-cell
proteins were extracted from GAE or vehicle (DMSO)-treated cells and subjected to
Western blot analysis for β- catenin. β-actin was used as loading control.

GAE activates caspase 3/7 and minimal PARP cleavage in breast cancer
MDA-MB 231 cells
Caspase-3/7 is essential in apoptotic cell death pathway. Therefore, in this
study, caspase 3/7 activity was evaluated in MDA-MB-231 cells incubated with 50,
70, and 100 μg/mL of GAE for 24 and 48 hrs to determine whether apoptosis was
associated with caspase 3/7 activation. The results show that after 24 hrs, caspase 3/7
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was activated significantly at 100 μg/mL of GAE. Treatment after 48 hrs increases
caspase 3/7 activity considerably at 50, 70, and 100 μg/mL compared to the control by
1.3, 1.5, and 3.6 folds, respectively (Figure 14). Moreover, Western blot analysis
showed a cleaved caspase 3 indicating the activation of caspases upon GAE treatment
during the 48 hrs (Figure 15A). Further, PARP expression was checked the by Western
blot, a well-known apoptosis marker, to confirm apoptosis induction in treated MDAMB-231 cells (Figure 15B). The results revealed a slight induction of PARP cleavage
at 100 μg/mL of GAE. Altogether, these findings suggest that GAE activates apoptosis
through a caspase-dependent pathway.

Figure 14: GAE activated caspase 3/7 in MDA-MB-231 cells. Caspase 3/7 activity in
MDA-MB-231 cells after exposure to GAE (50 to 70 μg/mL) for 24 and 48 hrs, relative
to a similar amount of viable DMSO-treated cells. The relative caspase 3/7 activity
was normalized to the number of viable cells per well and is express as fold of
induction compared to the control. The statistically significant difference was set at p
values of * 0.05, ** < 0.005, *** < 0.001 between control and treated groups.
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Figure 15: Western blot analysis of cleaved caspase 3 and PARP after 48 hrs of GAE
treatment in MDA-MB-231 cells. (A) cleaved caspase 3, (B) PARP, MDA-MB-231
cells were treated for 48 hrs with different concentrations of the GAE and proteins
were extracted from GAE or vehicle (DMSO)-treated cells and subjected to Western
blot analysis using cleaved caspase 3 (A) and PARP (B) antibodies. β-actin was used
as loading control.
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Chapter 4: Discussion
Currently, the treatment of cancer mainly includes radiotherapy, surgery and
chemotherapy. However, the curative effects of the existing chemotherapeutic drugs
in treating such multifactorial disease with agents targeting a single target might
provide partial treatment. Unfortunately, cure rates are disappointing in many cases as
patients usually develop drug resistance along with the numerous side effects of
treatment. TNBC is the most aggressive type of breast tumor with a high metastatic
rate, early recurrences, and poor survival prognosis and contributes to a large
proportion of breast cancer deaths despite its small proportion among all breast cancers
[62], [66], [67]. TNBC lack any standard targeted systemic therapy and is usually
treated with chemotherapy or radiotherapy, which causes severe side effects, and
showed limited long-term success [64], [135]. Therefore, searching for highly efficient
anti-cancer drugs remains one of the biggest challenges in medicine and deserves a
high priority of research to combat the enormous human suffering and related health
care. Among the potential alternatives that have emerged for treating cancer are anticancer agents from natural sources such as plants and dietary phytochemicals, marine
organisms and microorganisms. Through history, nature has been an attractive and rich
source of new therapeutic compounds that have found many applications in cancer
therapy as a tremendous scaffold diversity is found in millions of species of plants,
animals, marine organisms and microorganisms and are becoming an important area
for drug discovery [136].
Increasing knowledge and understanding on the hallmark characteristics of
cancer has led to the use of natural products such as phytochemicals and plants in
cancer therapy, which modulate several molecular targets and exert anticancer
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activities. Natural products have shown to exert therapeutic potential via modulation
of core hallmark capabilities of cancer. The activity comes from their ability to
suppress proliferative signaling, induce cell death, up-regulate growth suppressors,
deactivate invasion and metastasis, interact replicative immortality and attenuate
angiogenesis [136], [137]. Recent studies have significantly improved our
understanding of anti-cancer activities and underlying molecular mechanisms of many
anti-cancer agents derived from natural sources [138]. Targeted therapies against
signaling pathways involved in cell proliferation, metastasis, apoptosis, and cell cycle
regulation may provide a new insight into cancer therapeutics. If the study can
precisely activate or inhibit molecules that mediate the diversity of cell death
outcomes, perhaps it can succeed in more effective and less toxic chemotherapeutic
regimens.
Natural exudates, such as gums and resins produced from plants, have been
traditionally used for religious, cosmetics as well as medical purposes since ages.
Different types of gums and resins from plants have been used in traditional medicine
to treat variety of conditions including inflammatory diseases like arthritis, asthma,
chronic pain, bowel conditions and many other diseases. Although the use of plants
exudates and resins in traditional medicine has been commonly observed, few
pharmacological and chemical studies have been conducted on plant exudates and
resins concerning their scientific merits especially in the field of cancer therapy. Gum
Arabic is an edible, dried, gummy biopolymer exudates obtained from trees and
branches of Acacia senegal and Acacia seyal. In previous studies, Gum Arabic has
been found to possess several biological activities [139-141]. However, the anti-cancer
activity of GA has not been evaluated yet especially on TNBC.
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This study initial results, showed for the first time, that GAE exhibits
significant growth inhibitory effects on MDA-MB-231 and Hs578T (triple negative)
and MCF-7 (ER positive) breast cancer cell lines. As the growth inhibitory effect of
GAE in MDA-MB-231 was greater than that in MCF-7, the study focused on the effect
of GAE in TNBC MDA-MB-231 cell line. The two cell lines have different molecular
and histological characteristics. While, MDA-MB-231 cell line originated from
adenocarcinoma, estrogen, progesterone, and HER-2 receptors with a mutant p53 gene
(gain of function mutant p53), MCF-7 cells originated from adenocarcinoma, estrogen
receptor positive, and progesterone receptor negative harboring wild type p53 gene.
In MDA-MB-231 cells, GAE induces cell cycle arrest in G1/S phase
accompanied with alterations in several cell cycle regulatory proteins. A body of
evidence supported G1/S transition: (i) cyclin D1 downregulation in which its
inhibition was reported to play a role in G1/S transition. (ii) c-myc downregulation,
that is reported to be correlated with cellular proliferation, and it controls the G1/S
transition, and the (iii) upregulation of the CDK inhibitor p21WAF1, whose upregulation
can lead to apoptosis and disrupt CDKs/cyclin complexes necessary for cell cycle
progression during G1 and S phases transition. Cyclin D1 was downregulated upon
GAE treatment, which could be the leading cause for the G1 block as it was required
for G1 to S transition. The downregulation of cyclin B1 and cyclin A1, both are
involved in the G2/M phase transition, indicate that additional mechanisms might be
involved with GAE exposure. Interestingly, Kaempferol and Curcumin were also
reported to induce both G1/S arrest G2/M phase arrest in HT-29 cells and HOS cells,
respectively [142], [143]. The cell cycle arrest data are in agreement with the growth
inhibition data shown by cell viability.
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In MDA-MB-231, GAE could induce apoptotic cell death via activation of
apoptotic pathway. GAE significantly activates caspase 3/7 activity. Executioner
caspases-3 and -7 is activated in both the intrinsic and extrinsic apoptosis pathway by
caspase 9 or caspase 8. The activated caspase3/7 quickly start to break down proteins
resulting in eliminating abnormal cells [79]. A minimal cleavage of PARP was
detected by Western blot analysis. poly [ADP-ribose] polymerase (PARP) is involve
in repairing damaged DNA. It gets activated in response to DNA damage, and its also
a key marker in apoptosis activation [144]. The activation of PARP in important for
cell survival, as cells is very sensitive to its inhibition. PARP overexpression is usually
correlated with TNBC [145]. PARP cleavage lead to the inactivation of enzyme by
destroying its ability to respond to DNA strand breaks [146]. Further investigation of
which apoptosis pathways was triggered by GAE is ongoing in the lab. Moreover,
possible roles of ROS and DNA damage in GAE-induced anti-proliferative and cell
death are warranted.
Currently, majority of drugs used to treat cancer work at the molecular level to
induce cell death and inhibit the cell cycle progression, two fundamental strategies for
preventing malignant cell growth in the first place. Interestingly, numerous herbal
extracts from edible plants and their compounds have shown anti-cancer activities by
targeting these two events [59], [72].
Survivin is a member of the inhibitor of apoptosis (IAPs) proteins family that
represent anti-apoptotic proteins. Survivin has a unique structure making it a critical
factor in the modulation of cell division, cell cycle progression, and protection against
apoptosis by blocking caspase activation [147]. It has been assumed that survivin also
plays a role as a mitotic inducer [148]. In most breast cancer cases, survivin was
overexpressed, and its expression was correlated with tumor progression,
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chemotherapeutic resistance, and poor clinical outcomes [149]. Thus, targeting
survivin protein can serve as a promising treatment strategy for breast cancer patients.
The results demonstrated an initial increase in the survivin level at a lower
concentration of GAE (50 µg/mL), which might be explained by the cells' attempt to
survive. However, survivin was dramatically decreased at higher concentrations of
GAE treatment (70 and 100 µg/mL). Origanum majorana plant extract and
Salinomycin, a natural compound, were reported to induce survivin downregulation in
breast cancer cell line MDA-MB-231 [39], [150]. Therefore, the study suggest that
GAE exerts its anti-cancer effect at least partially through survivin's downregulation.
Wnt/ β-catenin pathway is highly regulated by β-catenin protein, which is
responsible for regulating mammary development and tumorigenesis. Dysregulation
of Wnt/ β-catenin was associated with breast cancer progression and metastasis [133],
[134]. In the present study, it was revealed that GAE decreased the b-catenin
expression in breast cancer cells MDA-MB-231. Notably, the inhibitory effect of GAE
on β-catenin signaling occurred at concentrations comparable to those required for
inhibiting cell viability and inducing apoptosis in these cells. These results indicate
that the anti-breast cancer activity of GAE was associated, at least partially, with its
inhibitory effects on Wnt/ β-catenin signaling pathway. Cyclin D1, c-myc and survivin
are established targets of Wnt signaling and their elevated expression are characterstics
of advanced breast cancer. The results support the idea that GAE may suppress c-myc,
cyclin D1, and survivin expression by blocking Wnt/β-catenin signaling. Increased
activity of the Wnt/ β- catenin signaling pathway is a common prporty of drug resistant
cancers, thus it is conceivable to use GAE as adjuvant with the chemotherapy regimen
that could improve the treatment of advanced breast cancer. A study has also reported
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that Sulforaphane downregulated the Wnt/ β- catenin self-renewal pathway in breast
cancer stem cells [151].
In summary, the data are consistent with a model shown in Figure 16. For the
first time, it was demonstrated that GAE inhibited the viability of the highly
proliferative and invasive human breast cancer cell line MDA-MB-231. The cell cycle
arrest at G1/S induced by GAE was accompanied by downregulation of cyclin D1, cmyc, and upregulation of p21WAF1. Moreover, a differential expression of survivin was
observed in cells treated with different GAE concentrations where survivin was
induced at low concentration and then abolished at higher concentrations. Finally,
GAE caused a massive decrease of β-catenin protein expression.

Figure 16: Proposed model demonstrating the underlying mechanism of action in GAE-induced anti-breast cancer activity in MDA-MB-231 cells
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Chapter 5: Conclusion

In conclusion, the present study demonstrated, for the first time, the potential
role of Gum Arabic as an anti-breast cancer agent in vitro. The study showed that
treatment of MDA-MB-231 TNBC cells with GAE inhibits cell proliferation, induces
cell cycle arrest and apoptosis through the down-regulation of cell cycle regulatory
proteins, downregulation of survivin and blocking β-catenin signaling pathway.
Further experiments are warranted to study the detailed molecular mechanisms of
action and downstream key players. Investigating Gum Arabic anti-cancer effect in
vivo is required to validate the in vitro findings.
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